65438 10 8, the negotiation of the national medical insurance drug list in 2022 ended. As for the highly anticipated therapeutic drugs in COVID-19, the negotiation between Afuddin tablets and Qingfei Jiedu Granules was successful, but the joint packaging of Naimativir tablets and Ritonavir tablets from Pfizer failed because the price was too high.
The market is in short supply, Paxlovid has become the focus of attention, and it is not surprising that it is expected to cut prices sharply.
But medical insurance negotiation is not a moral kidnapping, let alone an emotional robbery of robbing the rich and helping the poor. Behind the "soul bargaining", it is still a commercial game of exchanging price for quantity. Whether it can be successful in the end depends on whether the bottom line of medical insurance and enterprises intersects.
Because watching the medical insurance negotiations is not your own opposition, blindly follow the rhythm and follow the position. It is certainly gratifying that "P medicine" can win-win. If the negotiation fails, there is no need to over-interpret it, which will cause public opinion to be out of focus. After all, for medical insurance negotiations, Paxlovid is just an episode, not the norm.
Continuing the previous thinking, anticancer drugs and rare drugs are still the focus of this year's negotiations. At the level of system design, two new regulations, "simple renewal" and "non-exclusive drug bidding", were also implemented for the first time.
Today, people can still recall countless scenes of soul bargaining, such as "negotiating on behalf of the country, is it a drop of tens of cents?" The nervousness when an anticancer drug with a price of 6.5438+0.2 million yuan was unveiled, the excitement that a Nosaci sodium injection with a price of 700,000 yuan was reduced to 1 10,000 yuan after eight rounds of negotiations, and the feeling that "every small group should not give up".
Health care negotiations cannot just focus on Paxlovid. In the past four years, the National Medical Insurance Bureau has added 250 kinds of drugs, and the average price has dropped by more than 50%. 202 1 During the agreement period, 22 1 negotiated drug reimbursement 1 100 million person-times. Through negotiation of price reduction and medical insurance reimbursement, the patient's burden was reduced by 1 100 million yuan during the year.
Small changes on the negotiating table and the huge patient base will be amplified into huge interest adjustments, and its difficulty can be imagined. However, medical insurance negotiations are not blindly "cheap", and they are all indispensable from different angles such as drug cost effect, budget impact and medical insurance fund burden.
People's livelihood lies behind drugs. The positive significance of bargaining for the people and benefiting the people's medical insurance negotiations should not be concealed by the failure of a drug negotiation. Moreover, the current policy still leaves room and living space for drug protection under the epidemic situation. Medical insurance will still temporarily pay for a variety of COVID-19 drugs, including paciclovir, until March 3, this year1day.
On the market level, COVID-19-made oral drugs such as VV 1 16 from Junshi Bio and SIM04 17 from the voice have also been gearing up, and there are still many variables in the future supply, so the medical insurance negotiation is not "fixed for life at one time".